- Home
- RPID vs CCCC Comparison
RPID vs CCCC Comparison
Compare RPID & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPID | CCCC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.3M | 207.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RPID | CCCC |
|---|---|---|
| Price | $4.68 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.00 | $7.25 |
| AVG Volume (30 Days) | 335.0K | ★ 1.6M |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,523,000.00 | $30,108,000.00 |
| Revenue This Year | $19.36 | N/A |
| Revenue Next Year | $21.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.63 | N/A |
| 52 Week Low | $1.35 | $1.09 |
| 52 Week High | $4.88 | $3.84 |
Technical Indicators
Market Signals| Indicator | RPID | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 67.06 | 42.37 |
| Support Level | $4.01 | $2.07 |
| Resistance Level | $4.88 | $2.23 |
| Average True Range (ATR) | 0.40 | 0.13 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 89.29 | 5.32 |
Price Performance
Historical ComparisonAbout RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.